PMV Pharmaceuticals


Clinical-stage precision oncology company developing selective small-molecule therapies that restore the tumor-suppressing function of mutant p53 proteins. The organization pursues a tumor-agnostic approach focused on p53 hotspot mutations, supporting programs from discovery and IND-enabling preclinical studies through early-phase clinical trials and commercial launch readiness.

Industries

Biopharma
Biotechnology
Health Care
Medical Device
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

small (1-50)

PMV Pharmaceuticals

Princeton, New Jersey, United States


Patents

Uses of p53 x-ray co-crystal structures

US-12570645-B2

View Details

Methods and compounds for restoring mutant p53 function

US-12428406-B2

View Details

Companion diagnostic tool for mutant p53 reactivating compounds

US-12419880-B2

View Details

Deuterated compounds for restoring mutant p53 function

US-11963953-B2

View Details

Combination therapy for treatment of cancer

US-11938124-B2

View Details

Methods and compounds for restoring mutant p53 function

US-11926632-B2

View Details
View All Patents

Products

Investigational oral small-molecule p53 Y220C reactivator (pivotal candidate)

Orally administered investigational small molecule designed to bind the structural crevice created by the p53 Y220C mutation and stabilize the mutant protein to restore DNA-binding and tumor suppressor function; under clinical evaluation for advanced solid tumors harboring the Y220C mutation.


Services

Sponsorship and operational management of early-phase multicenter clinical trials for biomarker-defined oncology indications.

Case-by-case evaluation of requests for investigational product outside of clinical trials, including physician-led inquiries, regulatory coordination and ethical review.

Advisory board management, medical education, field-based scientific exchange and MSL support to investigators and pathologists.

Expertise Areas

  • Precision oncology targeting TP53 mutations
  • Small-molecule drug discovery and medicinal chemistry
  • Early-phase clinical development (Phase 1/2)
  • Regulatory strategy and IND-enabling packages
  • Show More (5)

Key Technologies

  • Small-molecule drug discovery
  • High-throughput biological screening
  • Medicinal chemistry
  • ADME/PK and pharmacology assays
  • Show More (7)

News & Updates


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.